Glucagon inhibition of secretin and combined secretin and cholecystokinin stimulated pancreatic exocrine secretion in health and disease.
The effect of glucagon infusion on secretin and combined secretin and cholecystokinin stimulated exocrine pancreatic secretion was studied in normal subjects and in patients after acute and with chronic pancreatic disease. Glucagon inhibited pancreatic protein secretion and had no inhibitory effect on volume or bicarbonate secretion.
D000208:Acute Disease; D001639:Bicarbonates / Q000378:metabolism; D001786:Blood Glucose / Q000032:analysis; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002908:Chronic Disease; D005934:Glucagon / Q000494:pharmacology*; D006801:Humans; D010179:Pancreas / Q000378:metabolism*; D010189:Pancreatic Juice / Q000378:metabolism*; D010195:Pancreatitis / Q000503:physiopathology*; D012633:Secretin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D012636:Secretory Rate / Q000187:drug effects
D001639:Bicarbonates; D001786:Blood Glucose; D012633:Secretin; D005934:Glucagon; D002766:Cholecystokinin